Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RGNX | INSIDER-BUY | bullish | 5/10 | Director Gregory Ciongoli made a $450K open-market purchase of RGNX shares at $9.14 on August 26, adding to a $500K purc | Aug 27, 2026 |
| GRML | 8-K | bearish | 8/10 | Greenland Mines Ltd closed a registered public offering of 1,632,783 shares of common stock and pre-funded warrants for | Aug 27, 2026 |
| IMTX | INSIDER-BUY | bullish | 6/10 | Director Perceptive Advisors LLC purchased 863,060 shares of Immatics N.V. for $7.5M at $8.69/share in a single open-mar | Aug 27, 2026 |
| LFVN | PRESS-RELEASE | bearish | 7/10 | LifeVantage reported Q4 FY2026 revenue of $42.4M (down 23.1% YoY) and GAAP EPS of $0.10 (down from $0.15 YoY), missing c | Aug 27, 2026 |
| ROIV | PRESS-RELEASE | bullish | 8/10 | Priovant Therapeutics, a Roivant (ROIV) company, announced FDA approval of LISRAYA (brepocitinib) for adult dermatomyosi | Aug 27, 2026 |
| ROIV | PRESS-RELEASE | bullish | 8/10 | FDA approved LISRAYA (brepocitinib) for adult dermatomyositis, the first targeted therapy for this indication. Approval | Aug 27, 2026 |
| CUVL | 6-K | neutral | 3/10 | Clinuvel Pharmaceuticals filed its annual report, corporate governance disclosures, and investor presentation with the A | Aug 27, 2026 |
| GRML | PRESS-RELEASE | mixed | 6/10 | Greenland Mines announced it expects to complete the acquisition of Neo North Star Resources (Sarfartoq Nd-Pr rare earth | Aug 27, 2026 |
| GRML | 424B5 | bearish | 7/10 | Greenland Mines Ltd is conducting a best-efforts offering of up to 4,000,000 shares of common stock and/or pre-funded wa | Aug 27, 2026 |
| ENTX | PRESS-RELEASE | neutral | 2/10 | Entera Bio announced that CEO Miranda Toledano will present at three upcoming investor conferences (Cantor, Guggenheim, | Aug 27, 2026 |
| FBRX | 25-NSE | bearish | 9/10 | Nasdaq filed a Form 25-NSE with the SEC on August 27, 2026, to remove Forte Biosciences (FBRX) common stock from listing | Aug 27, 2026 |
| JUNS | 8-K | bearish | 7/10 | Jupiter Neurosciences disclosed that four executive officers and directors irrevocably forgave an aggregate of $875,315 | Aug 27, 2026 |
| BHC | PRESS-RELEASE | neutral | 1/10 | Bausch Health announced the recipients of its 2026 Aspire Higher Scholarship Program, awarding six students up to $10,00 | Aug 27, 2026 |
| RADX | 6-K | neutral | 2/10 | Radiopharm Theranostics filed a 6-K with the ASX reporting that four directors (Riccardo Canevari, Paul Hopper, Ian Turn | Aug 27, 2026 |
| MBX | PRESS-RELEASE | bullish | 8/10 | MBX Biosciences announced the first patient dosed in its pivotal Phase 3 oPTimize trial for once-weekly canvuparatide in | Aug 27, 2026 |
| MESO | 20-F | bullish | 6/10 | Mesoblast filed its annual 20-F for FY2026, reporting first full-year product revenue of $115.2M from Ryoncil (approved | Aug 27, 2026 |
| CYCN | 8-K | bullish | 7/10 | Cyclerion Therapeutics shareholders approved all key proposals to advance the merger with Korsana Biosciences, including | Aug 27, 2026 |
| NCEL | EFFECT | bearish | 5/10 | NewcelX Ltd. received SEC effectiveness on August 26, 2026 for its F-3 shelf registration (File No. 333-298458), enablin | Aug 27, 2026 |
| BAK | 6-K | bearish | 6/10 | Braskem disclosed a related-party transaction increasing its commercial credit limit with co-controlling shareholder Pet | Aug 27, 2026 |
| OPTH | 6-K | bearish | 6/10 | Optimi Health Corp. entered into an equity line of credit (ELOC) with Seven Knots, LLC, securing the right to sell up to | Aug 27, 2026 |
| RAPP | CLUSTER | neutral | 3/10 | Two top insiders at Rapport Therapeutics (CEO and Chief Development Officer) sold a combined ~$1.98M in open-market sale | Aug 27, 2026 |
| CSTL | CLUSTER | bearish | 5/10 | Two C-suite insiders at Castle Biosciences sold a combined $463K in open-market sales over a week, with the COO alone se | Aug 27, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt executed a large cluster of open-market sales totaling approximately $12.5M over Aug 21-25, alongs | Aug 27, 2026 |
| CUVL | PRESS-RELEASE | mixed | 5/10 | Clinuvel Pharmaceuticals reported FY2026 annual results with revenue of $94.0M (down 1% YoY) and net profit after tax of | Aug 27, 2026 |
| TEVA | COURT-RULING | neutral | 2/10 | A federal magistrate judge in Kansas granted in part and denied in part a motion to compel non-party law firm Goodwin Pr | Aug 26, 2026 |
| TRDA | CLUSTER | neutral | 3/10 | Two MPM BioVentures funds, each a 10% owner of Entrada Therapeutics, sold a combined ~$400K in open-market sales over th | Aug 26, 2026 |
| MESO | PRESS-RELEASE | bullish | 7/10 | Mesoblast reported FY2026 total revenue of $120.3M, up 7x from $17.2M in FY2025, driven by the first full year of RYONCI | Aug 26, 2026 |
| IRON | CLUSTER | neutral | 3/10 | Two C-suite insiders at Disc Medicine (IRON) sold a total of $681K in open-market sales over a one-week window, with CEO | Aug 26, 2026 |
| SPRC | 6-K | neutral | 3/10 | SciSparc announced the addition of Prof. Carmel Domshlak, an internationally recognized AI expert from Technion, to its | Aug 26, 2026 |
| IMTX | 6-K | bearish | 6/10 | Immatics N.V. completed a public offering of 15,535,100 ordinary shares and pre-funded warrants to purchase 4,315,304 or | Aug 26, 2026 |